Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Molecular Pain|August 18, 2017
Analgesia by Deletion of Spinal Neurokinin 1 Receptor Expressing Neurons Using a Bioengineered Substance P-Pseudomonas Exotoxin ConjugateMichael J Iadarola, Matthew R Sapio, Xunde Wang, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Immunization with peptide encapsulated within synthetic spores activates T cell responses and reduces tumor growthDomenico D'Atri, Elena Tondini, Federico Machinandiarena, et al.
Mbio|September 12, 2025
Immunization with peptide encapsulated within synthetic spores activates T cell responses and reduces tumor growthDomenico D'Atri, Elena Tondini, Federico Machinandiarena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemiaRobert J Kreitman, Martin S Tallman, Tadeusz Robak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialAlan S Wayne, Robert J Kreitman, Harry W Findley, et al.
Infection and Immunity|October 22, 2005
Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cellsJennifer C Hsieh, Doris M Tham, Weijun Feng, et al.
Leukemia & Lymphoma|May 24, 2011
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737David J Fitzgerald, Elizabeth Moskatel, Gal Ben-Josef, et al.
Plos One|August 25, 2016
Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion ProteinsAntonella Antignani, Lesley Mathews Griner, Rajarshi Guha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 5, 2006
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patientsMasanori Onda, Satoshi Nagata, David J FitzGerald, et al.
Blood|March 1, 2018
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-upRobert J Kreitman, Martin S Tallman, Tadeusz Robak, et al.
Pageof 5